In the complex, high-stakes machinery of the American healthcare system, few companies are as indispensable—yet as quietly influential—as McKesson Corporation (NYSE: MCK). As of March 18, 2026, McKesson stands not merely as a distributor of pills and medical supplies, but as a sophisticated healthcare services platform that has successfully pivoted from low-margin logistics to high-value [...]
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...
The latest data from the U.S. Census Bureau, released in late February 2026, suggests a surprising degree of resilience within the American supply chain. Wholesale inventories for December 2025 rose by a modest 0.2%, reaching a total of $918.0 billion. This figure, which aligns perfectly with analyst
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. While the market's reaction was initially described as a "bumpy ride" due to concerns in other sectors, the favorable inflation data ultimately helped calm Wall Street. Lower inflation is a key prerequisite for the central bank to ease its monetary policy, which is generally supportive of stock valuations.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncology acquisition as pivotal to driving both revenue and operating income growth. The quarter was also shaped by strong sales of GLP-1 medications and the company’s ongoing focus on supporting specialty care providers.
McKesson Corporation (NYSE: MCK) stands today as the undisputed titan of the U.S. pharmaceutical supply chain. While the company has long been a staple of the Fortune 500, its relevance has surged in early 2026 as it navigates a complex landscape of drug shortages, revolutionary new therapies, and a massive internal restructuring. The company is [...]
Shares of healthcare distributor Cencora (NYSE:COR)
jumped 7.1% in the afternoon session after the company reported first-quarter results that beat profit expectations and raised its full-year guidance.
Healthcare distributor Cencora (NYSE:COR) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 5.5% year on year to $85.93 billion. Its non-GAAP profit of $4.08 per share was 1% above analysts’ consensus estimates.
Healthcare distributor Cencora (NYSE:COR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 5.5% year on year to $85.93 billion. Its non-GAAP profit of $4.08 per share was 1% above analysts’ consensus estimates.
The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative progress and pharmaceutical innovation. On January 8, 2026, the U.S. House of Representatives passed a crucial bill
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 19.9% gain over the past six months, beating the S&P 500 by 9.1 percentage points.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
